{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:13:15Z","timestamp":1758046395913,"version":"3.44.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.pharma.2011.02.002","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T17:52:13Z","timestamp":1303494733000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Int\u00e9r\u00eats et limites de l\u2019inhibition de la r\u00e9nine par l\u2019aliskiren"],"prefix":"10.1016","volume":"69","author":[{"given":"M.","family":"Azizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Steichen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2011.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0010","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1161\/01.CIR.0000131449.94713.AD","article-title":"Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1\u00a0receptor antagonists","volume":"109","author":"Azizi","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2011.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0020","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2\u00a0diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0025","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2\u00a0diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0030","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN Group","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0040","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pharma.2011.02.002_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0050","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0055","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0060","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0070","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000\u00a0patients in randomized trials","volume":"97","author":"Inhibitor Myocardial Infarction Collaborative A.C.E Group","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2011.02.002_bib0075","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0085","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.pharma.2011.02.002_bib0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.HYP.16.4.363","article-title":"Angiotensin I converting enzyme and the changes in our concepts through the years","volume":"16","author":"Erd\u00f6s","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0095","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.HYP.31.1.356","article-title":"Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system","volume":"31","author":"Iyer","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1172\/JCI118484","article-title":"Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem-cell regulator N-acetyl-seryl-aspartyl-lysyl-proline","volume":"97","author":"Azizi","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharma.2011.02.002_bib0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","article-title":"Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology","volume":"117","author":"Israili","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0110","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"351","author":"Nussberger","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1681\/ASN.2004100874","article-title":"Renin inhibition: what are the therapeutic opportunities?","volume":"16","author":"Fisher","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharma.2011.02.002_bib0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003088-199529010-00002","article-title":"Clinical pharmacokinetics and efficacy of renin inhibitors","volume":"29","author":"Rongen","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1074-5521(00)00134-4","article-title":"Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin","volume":"7","author":"Rahuel","year":"2000","journal-title":"Chem Biol"},{"key":"10.1016\/j.pharma.2011.02.002_bib0130","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharma.2011.02.002_bib0135","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1073\/pnas.89.16.7806","article-title":"Species specificity of renin kinetics in transgenic rats harboring the human renin angiotensinogen genes","volume":"89","author":"Ganten","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2011.02.002_bib0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.hjh.0000202812.72341.99","article-title":"Renin inhibition with aliskiren: where are we now, and where are we going?","volume":"24","author":"Azizi","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharma.2011.02.002_bib0145","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003088-200847080-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of aliskiren","volume":"47","author":"Vaidyanathan","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2165\/00003088-200645110-00006","article-title":"Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2\u00a0diabetes mellitus","volume":"45","author":"Zhao","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0160","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200746080-00003","article-title":"Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment","volume":"46","author":"Vaidyanathan","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0165","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/clpt.2010.101","article-title":"Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1\u00a0and CYP3A4\u00a0substrate aliskiren","volume":"88","author":"Tapaninen","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharma.2011.02.002_bib0170","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1185\/03007990802259354","article-title":"A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects","volume":"24","author":"Vaidyanathan","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharma.2011.02.002_bib0175","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1097\/01.ASN.0000146686.35541.29","article-title":"Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1\u00a0Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption","volume":"15","author":"Azizi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharma.2011.02.002_bib0180","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00004872-198406000-00010","article-title":"Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall","volume":"2","author":"Okunishi","year":"1984","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharma.2011.02.002_bib0185","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","article-title":"Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart","volume":"265","author":"Urata","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharma.2011.02.002_bib0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.HYP.35.1.155","article-title":"Role of the angiotensin type 2\u00a0receptor in the regulation of blood pressure and renal function","volume":"35","author":"Carey","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0195","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.0000096609.73772.C5","article-title":"Can angiotensin II type 2\u00a0receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system","volume":"109","author":"Levy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2011.02.002_bib0200","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/01.HYP.0000193498.07087.83","article-title":"The continuing saga of the AT2\u00a0receptor: a case of the good, the bad, and the innocuous","volume":"46","author":"Reudelhuber","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(25)06820-6","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors","volume":"47","author":"Linz","year":"1995","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharma.2011.02.002_bib0210","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/ki.1996.511","article-title":"Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1\u00a0antigen","volume":"50","author":"Nguyen","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharma.2011.02.002_bib0215","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharma.2011.02.002_bib0220","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.ki.5000011","article-title":"Renin increases mesangial cell transforming growth factor-beta1\u00a0and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms","volume":"69","author":"Huang","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharma.2011.02.002_bib0225","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/HYPERTENSIONAHA.107.101444","article-title":"Prorenin and renin-induced extracellular signal-regulated kinase 1\/2\u00a0activation in monocytes is not blocked by aliskiren or the handle-region peptide","volume":"51","author":"Feldt","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0230","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","article-title":"Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27\u00a0rats","volume":"52","author":"Feldman","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0235","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJM198505303122202","article-title":"Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications","volume":"312","author":"Luetscher","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0240","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s001250051260","article-title":"Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus","volume":"42","author":"Deinum","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharma.2011.02.002_bib0245","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1517\/13543784.15.10.1137","article-title":"Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension","volume":"15","author":"Ichihara","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharma.2011.02.002_bib0250","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/HYPERTENSIONAHA.108.127258","article-title":"Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma","volume":"53","author":"Cousin","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0255","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2011.02.002_bib0260","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2011.02.002_bib0265","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2011.02.002_bib0270","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","article-title":"Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial","volume":"26","author":"Andersen","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharma.2011.02.002_bib0275","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0280","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/jhh.2008.162","article-title":"Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review","volume":"23","author":"Musini","year":"2009","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharma.2011.02.002_bib0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":"Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide","volume":"25","author":"Villamil","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharma.2011.02.002_bib0290","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1185\/03007990902785845","article-title":"Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension","volume":"25","author":"Littlejohn","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharma.2011.02.002_bib0295","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.106.084301","article-title":"Direct renin inhibition with aliskiren in obese patients with arterial hypertension","volume":"49","author":"Jordan","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0300","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","article-title":"Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker","volume":"49","author":"O\u2019Brien","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0305","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ndt\/15.5.637","article-title":"Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function","volume":"15","author":"van Paassen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2011.02.002_bib0310","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2337\/dc09-1303","article-title":"Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1\u00a0diabetes: a pilot study","volume":"33","author":"Cherney","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2011.02.002_bib0315","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s00125-010-1789-6","article-title":"Optimal antiproteinuric dose of aliskiren in type 2\u00a0diabetes mellitus: a randomised crossover trial","volume":"53","author":"Persson","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharma.2011.02.002_bib0320","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","article-title":"Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2\u00a0diabetes, hypertension, and albuminuria","volume":"32","author":"Persson","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharma.2011.02.002_bib0325","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2\u00a0diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2011.02.002_bib0330","doi-asserted-by":"crossref","unstructured":"Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2\u00a0diabetes and nephropathy. Diabetes Care 2010;33:2304\u20139.","DOI":"10.2337\/dc10-0833"},{"key":"10.1016\/j.pharma.2011.02.002_bib0335","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0340","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2\u00a0Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2011.02.002_bib0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharma.2011.02.002_bib0350","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1470320309104662","article-title":"Managing cardiovascular and renal risk: the potential of direct renin inhibition","volume":"10","author":"Sever","year":"2009","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharma.2011.02.002_bib0355","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation.$"},{"key":"10.1016\/j.pharma.2011.02.002_bib0360","unstructured":"Solomon SD. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with left ventricular dysfunction: ASPIRE. Late breaking clinical science. Paper presented at: American College of Cardiology, 2010; Atlanta."},{"key":"10.1016\/j.pharma.2011.02.002_bib0365","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharma.2011.02.002_bib0370","first-page":"128","article-title":"[Pharmacovigilance update]","volume":"6","author":"Livio","year":"2010","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.pharma.2011.02.002_bib0375","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2011.02.002_bib0380","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa055202","article-title":"Major congenital malformations after first-trimester exposure to ACE inhibitors","volume":"354","author":"Cooper","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450911000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450911000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:28:48Z","timestamp":1757719728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450911000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0003450911000307"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2011.02.002","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Int\u00e9r\u00eats et limites de l\u2019inhibition de la r\u00e9nine par l\u2019aliskiren","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2011.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}